Keratin immunohistochemistry does not contribute to correct lymph node staging in patients with invasive lobular carcinoma

Human Pathology

Volumn 39, Issue 7, 2008, Pages 1011-1017

  Patil, Deepa T ^a   Susnik, Barbara ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cytokeratin; Lobular; Sentinel lymph node

Indexed keywords

CYTOKERATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; SENTINEL LYMPH NODE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 45049087493     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.11.017     Document Type: Article

References (35)

1. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
2. Brogi E., Torres-Matundan TE., Tan L.K., et al. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol 12 (2005) 173-180
3. Weiser M.R., Montgomery L.L., Susnik B., et al. Is routine intraoperative frozen-section examination of sentinel lymph nodes in breast cancer worthwhile?. Ann Surg Oncol 7 (2000) 651-655
4. Ryden L., Chebil G., Sjostrom L., et al. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumor cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol 33 (2007) 33-38
5. Grube B.J., Hansen N.M., Ye X., et al. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 184 (2002) 372-376
6. Cserni G., Bianchi S., Vezzosi V., et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 59 (2006) 518-522
7. Cserni G., Bianchi S., Boecker W., et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 103 (2005) 358-367
8. Singletary S.E., Greene F.L., and Sobin L.H. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 98 (2003) 2740-2741
9. Singletary S.E., and Greene F.L. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21 (2003) 53-59
10. Acs G., Lawton T.J., Rebbeck T.R., et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115 (2001) 85-98
11. Dowlatshahi K., Fan M., Anderson J.M., et al. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 8 (2001) 675-681
12. Cummings M.C., Walsh M.D., Hohn B.G., et al. Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol 26 (2002) 1286-1295
13. Wilkinson E.J., Hause L.L., Hoffman R.G., et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu 17 Pt 2 (1982) 67-91
14. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 335 (1990) 1565-1568
15. Cote R.J., Peterson H.F., Chaiwun B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354 (1999) 896-900
16. Hainsworth P.J., Tjandra J.J., Stillwell R.G., et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 80 (1993) 459-463
17. Nasser I.A., Lee A.K., Bosari S., et al. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 24 (1993) 950-957
18. McGuckin M.A., Cummings M.C., Walsh M.D., et al. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 73 (1996) 88-95
19. Colpaert C., Vermeulen P., Jeuris W., et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumor. J Pathol 193 (2001) 442-449
20. Trojani M., de Mascarel I., Coindre J.M., et al. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 56 (1987) 838-839
21. de Mascarel I., MacGrogan G., Picot V., et al. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 87 (2002) 70-74
22. Millis R.R., Springall R., Lee A.H., et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 86 (2002) 396-401
23. Creager A.J., Geisinger K.R., Perrier N.D., et al. Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast. Ann Surg 239 (2004) 61-66
24. Bussolati G., Gugliotta P., Morra I., et al. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 54 (1986) 631-636
25. de Mascarel I., Soubeyran I., MacGrogan G., et al. Immunohistochemically detected lymph node metastases from breast carcinoma: practical considerations about the new American Joint Committee on Cancer classification. Cancer 103 (2005) 1319-1322
26. Klevesath M.B., Bobrow L.G., Pinder S.E., et al. The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. Br J Cancer 92 (2005) 2201-2205
27. Susnik B., Frkovic-Grazio S., and Bracko M. Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: a case-control study with 15-year follow-up. Ann Surg Oncol 11 (2004) 568-572
28. Byrne J., Horgan P.G., England S., et al. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer 28 (1992) 658-660
29. de Mascarel I., Bonichon F., Coindre J.M., et al. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 66 (1992) 523-527
30. Amin B.D., and Hoda S.A. Minimal metastatic disease in sentinel lymph nodes in breast carcinoma: some modest proposals to refine criteria for "isolated tumor cells". Adv Anat Pathol 13 (2006) 185-189
31. Cserni G., Amendoeira I., Apostolikas N., et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 57 (2004) 695-701
32. van Rijk M.C., Peterse J.L., Nieweg O.E., et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 107 (2006) 467-471
33. Calhoun K.E., Hansen N.M., Turner R.R., et al. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg 190 (2005) 588-591
34. Viale G., Maiorano E., Pruneri G., et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 241 (2005) 319-325
35. Smeets A., and Christiaens M.R. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol 17 (2005) 539-544